Bicara Therapeutics: Raben proposes $449K share sale
The notice names Morgan Stanley Smith Barney LLC as broker and gives an aggregate market value of $449,026.14.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bicara Therapeutics Inc. officer David Raben reported a proposed sale of 24,777 common shares, with an approximate sale date of October 21, 2026. The notice lists Morgan Stanley Smith Barney LLC as broker and an aggregate market value of $449,026.14. It identifies the shares as acquired through a stock option exercise from the issuer on October 21, 2026, with cash shown as payment.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.